Own-brand peptide and GLP-1 stores

The research was done by AI agents that open web pages. Some sites refuse them; where that happened we say so. The small numbers point to the source list at the end. Where a figure is our own sum or guess, it is marked “our estimate” and the basis is given.

The claim

Our collection for this scheme holds one tweet, collected on 6 October 2026¹. It is an example of the claim. The page judges the scheme, not the person who tweeted.

If you want to make money online, not sure why you wouldn’t sell peptides.

What do you think will sell better? A GLP or a fidget toy from Ali express?

Here’s how to build a peptide brand to 7 figures

THREAD

@King_Lou_IV, 3,023 views when collected¹

The account had 9,851 followers when collected, which we treat as about 10,000 under our naming rule¹. The tweet had 6,163 views when we opened it on 10 October 2026².

The thread has six more posts². Among other points, it advises a “research focused” website with disclaimers and lab certificates; a trusted supplier found through referrals; and “an organic distribution system. Affiliates. Ai content.” It says: “Always use affiliate accounts to post content, never from your main brand account.” It says email is “where the money is made”, and: “You could have $5k LTV customers within months.” LTV means lifetime value, the total a customer spends over time. It ends: “Once in a lifetime opportunity to sell peptides over the next 2 years.”²

The text gives no price, cost, order volume or legal status, and no source for the $5,000 figure¹². It does not mention paid adverts. We read the text of the thread; its images and videos, and the replies under it, were not viewed.

With one tweet, the rest of this page rests on how the method is promoted and practised generally, and on public records.

What the scheme is

A peptide is a short chain of amino acids, the building blocks of proteins. Some peptides are medicines. GLP-1 drugs are the best known: semaglutide (sold as Ozempic and Wegovy) and tirzepatide are prescription drugs used for diabetes and weight loss. Others, such as retatrutide, are still in trials and are not approved for anything²².

“Build a peptide brand” covers three different businesses.

1. The “research use only” web store. The seller buys vials of peptide powder, mostly from factories abroad, puts a brand label on them and sells them online with a notice that they are “for research use only” and “not for human consumption”. This is the version the thread describes². The US drug regulator, the Food and Drug Administration (FDA), says selling GLP-1 products this way is illegal²².

2. The telehealth brand. Telehealth means medical care over the internet. Here a licensed clinician prescribes, and a licensed pharmacy makes the drug to order, which is called compounding. The brand owner runs the website and the advertising and rents the medical side from a platform company⁶⁴.

3. The non-drug product. Collagen powders and skin creams that contain peptides are sold as supplements or cosmetics. One store-software company’s guide marks these as legal to sell online and treats them as an ordinary private-label business (a factory makes the product and you put your label on it)⁵⁰. It is not what the tweet means by “a GLP”.

The three have different rules, costs and outcomes. This page judges mainly the first two. The third gets a short sum below, from one vendor’s guide only.

The arithmetic

“Seven figures” means at least $1,000,000. The tweet does not say whether that is sales or profit, or over what period¹. We take it as $1,000,000 of sales in a year.

Step 1: price and cost of a vial

A testing lab, Finnrick, publishes a price table for retatrutide. It listed 378 vendors on 10 October 2026, and 8 were visible without logging in³. The 8 are the table’s top-rated vendors, not a sample of all 378³. Two US-facing resellers charged $4.79 and $6.40 per milligram. Six suppliers, mostly in China, charged $0.60 to $1.23 per milligram³. One of the two resellers, Peptide Partners, is among five stores that received FDA warning letters in August 2026, by a law firm’s account²⁶.

For a 10 mg vial that gives (our sums):

• Retail price: $4.79 x 10 = about $48, up to $6.40 x 10 = $64.
• Product cost: $0.60 x 10 = $6, up to $1.23 x 10 = about $12.

So the product itself costs roughly 9% to 26% of the retail price (our division: $6 of $64, up to $12 of $48), and about 16% at the mid-points of $9 and $55. We could not get a manufacturer’s own price list.

Step 2: how many vials make $1,000,000

These are our estimates: $1,000,000 divided by the price, using the prices in³.

Step 3: what is left per vial

Take a $55 vial sold one to an order. Our estimate, using sourced rates where we have them:

• Product: about $9 (the middle of $6 to $12)³.
• Card fees: 4% to 8%, so $2.20 to $4.40. The range is our estimate. It sits between one vendor guide’s 3.49% to 3.95% plus about 25 cents¹¹ and one store’s stated 7% of sales⁵⁴.
• Affiliate commission: 10% to 15%, so $5.50 to $8.25¹⁹²⁰. An affiliate is someone who promotes the product and is paid a share of each sale.
• Shipping: $5. This is our assumption; we found no source.

$55 minus these leaves about $28 to $33 per vial. That is before lab testing, refunds, legal advice, held-back payments and the owner’s time.

On that basis $1,000 a month takes about 30 to 36 vials a month, and $10,000 a month about 300 to 360 (our estimate). The hard parts are the next three steps.

Step 4: taking card payments

An ordinary online store pays about 2.9% plus 30 cents per card payment on Shopify’s basic plan, which costs $39 a month⁸. A peptide store generally cannot use that route.

Stripe, a large card processor, publishes a list of businesses it prohibits or restricts. It includes “Incorrectly labeled research chemicals”, online pharmacies and telehealth⁶. Stripe’s help page says: “A large number of peptides are prescription only and are required to be sold by pharmacies, meaning Stripe must preapprove the merchant”⁷.

Sellers therefore use “high-risk” processors. One such processor’s general guide gives rates of 3.49% to 3.95% plus about 25 cents. It says processors hold back a reserve, a share of sales kept as security: they “typically hold 5% to 10% of processing volume (higher-risk accounts may see 15%+), with hold windows of 90 to 180 days”¹¹. A company that sells payment services to peptide stores gives 5% to 20%¹². These are vendors’ figures.

At $1,000,000 a year ($83,333 a month), that ties up about $12,500 (5% for 90 days) to $50,000 (10% for 180 days), our estimate.

Even the specialists draw a line. One processor that serves peptide businesses states: “We do not support research-use-only (RUO) peptide sellers.” It takes licensed clinics, telehealth firms and pharmacies¹⁰.

Step 5: finding customers

The scheme as we defined it scales with paid marketing. For the research-store version the main advertising platforms are largely closed.

• Meta (Facebook and Instagram) allows prescription-drug adverts only from certified sellers: “Meta requires online pharmacies and telehealth providers to be actively certified with LegitScript.”¹³ LegitScript is a private company that checks health sellers.
• Google does not allow adverts for unapproved substances, including “Products that have been subject to any government or regulatory action or warning”. Online pharmacies need LegitScript certification and Google’s own¹⁴.
• TikTok lists prescription medicine as “Not allowed” in most countries. In the United States it “may be allowed” only with proof of approval from the regulator, “such as the US Food and Drug Administration (FDA)”, and for audiences aged 18 or over¹⁵. An unapproved peptide cannot meet that condition (our reading).
• Amazon lists “GLP-1 (Glucagon-like peptide-1) agonists” among prohibited drug listings¹⁶.

LegitScript’s standard certification costs $975 per website to apply (non-refundable) plus $2,150 a year, so $3,125 in the first year¹⁷. A probationary tier costs $3,995 a year instead, so $4,970 in the first year (our sum)¹⁷. Certification is for licensed pharmacies and telehealth providers, and LegitScript says its rules bar certified businesses from offering or advertising the popular unapproved peptides¹⁸. None of the Meta or Google pages names peptides; that their rules cover them is our reading¹³¹⁴.

The thread does not propose paid adverts. It proposes affiliates and “organic” content, meaning posts that are not paid adverts². That fits the closed advertising routes, though the thread gives no reason. Published affiliate terms for research-peptide brands are mostly 10% of each sale¹⁹²⁰. One network listing shows 70% on a new customer’s first order and 5% after²¹. The workaround does work for some stores: two small stores listed for sale say they grew without paid adverts, and one of them says affiliates bring 51% of its sales⁷³⁷⁴. It does not remove the legal exposure described below⁶⁰.

How much traffic would a store need for $1,000,000? Two rough estimates, both ours:

• On general e-commerce averages: conversion rates (the share of visits that end in a purchase) of 1.4% and 2.66%⁴⁰ and a $110 order of two vials (our assumption) give about 9,100 orders and 340,000 to 650,000 visits a year.
• On figures for peptide stores from Grips Intelligence, a tool that models stores’ sales from web traffic: orders of $100 to $250 and conversion of 3.0% to 3.5%⁷⁵⁴³ give 4,000 to 10,000 orders and about 115,000 to 330,000 visits.

The thread’s “$5k LTV customers within months” can be tested the same way. At $100 to $250 an order, $5,000 is 20 to 50 orders from one customer (our estimate, using⁷⁵⁴³). A customer who buys monthly takes more than a year and a half to get there. One store for sale states a “35.6% repeat customer rate”, which means most of its buyers had not yet come back after 8 months⁷⁴.

Step 6: the law

This step decides the rest. The FDA says the “research” label does not make the sale legal, and it has said so in letters to stores that used the same wording the thread advises²²²³. So the per-vial sums describe a business the regulator can stop at any time. The detail is under “What the rules allow now”.

The telehealth version

The sums are different for the licensed route. Hims & Hers is a large US telehealth company listed on the stock market. Its annual report to the US securities regulator shows $83 of revenue per subscriber per month in 2025, across all its products, not only GLP-1 drugs³⁸. It shows a 74% gross margin (what is left of sales after the cost of the product) and $919.3 million of marketing against $2,347.6 million of revenue³⁸. That is 39 cents of marketing per dollar of sales (our division). Gross margin fell to 64% in April to June 2026, from 76% a year earlier³⁹.

All four subscriber counts are our estimates: $1,000,000 divided by 12, divided by the monthly figure. Patients who leave must be replaced, so the sign-ups needed are higher.

At the Hims & Hers ratio, $1,000,000 of sales would come with about $390,000 of marketing (our estimate)³⁸. Triple Whale, an advertising-analytics company, publishes figures from over 40,000 brands that use its software, for August 2025 to July 2026. For health and wellness brands the median advertiser got $1.44 of sales per dollar of Meta adverts and paid $40.53 per purchase traced to an advert⁴¹. At that rate the advert cost is 69% of the sales the adverts bring in (our sum: 1 divided by 1.44). Sales from email, search and repeat orders come on top, so the share of total sales is lower. This is not GLP-1 data; it covers lawful health brands in general. We found no reliable figure for what it costs to win one GLP-1 patient or how long a patient stays.

The non-drug version

One store-software company’s guide gives its own estimates for a peptide skin serum: a $9 product sold at $45 leaves about $15.40 after fees, shipping, returns and marketing⁵⁰. It puts starting costs at about $8,000 to $20,000 and advises: “Plan for 12 to 18 months of cash flow before things turn green.”⁵⁰ These are a vendor’s estimates, not results. We did not research this version further.

What people who tried it report

We found no published income report with proof from a peptide brand owner, and no representative data on what share of these stores earn anything. What exists is court records, regulator letters, closures, sale listings and journalism.

A long list of vendors. Finnrick’s list of retatrutide vendors held 179 names in May 2026, by Public Citizen’s count, and 378 on 10 October 2026⁴³. The list includes factories abroad, and we cannot tell new sellers from wider testing by the lab. Public Citizen, a consumer advocacy group, reported that the lab rated 71 of the 179 (about 40%) in its three lowest grades⁴.

Tracked sales fell in 2026. Grips estimates that the peptide stores it tracks sold $99 million online in 2025, “up 50%+ from the previous year”, and says: “For 2026, revenue is expected to decline by 50%+.”⁷⁵ It shows $969,000 of sales in August 2026 across “10+” tracked stores, and a 72% fall in its sales index from March to August⁷⁵. Most of that fall is one store: the same tool puts Peptide Sciences at $81.3 million of 2025 sales, and it closed in March⁴³⁴². These are a model’s estimates from about ten stores, not a count of the market.

Small stores for sale. Flippa is a marketplace where online businesses are sold. Three research-peptide stores were listed there on 10 October 2026:

• A US store, 10 months old: profit of $3,103 a month at a 41% margin; asking $80,000 including $30,000 of stock⁷².
• A US store at peptidelabsinc.com, 1 year old: profit of $3,091 a month; asking $100,000. The seller’s text claims “$20,000 in monthly revenue with a 75% profit margin, without using paid advertising”, which does not match the profit figure Flippa shows⁷³.
• A store selling to Australian customers, 8 months old: profit of AUD 22,702 a month, about US$16,000 at the listing’s own exchange rate (our conversion). The seller states “100% organic growth without any paid advertising” and that an affiliate network drives 51% of revenue. The asking price was marked “Reduced 21%”⁷⁴.

Flippa marks all three as checked by its team for revenue, main expenses and traffic; two also connected their store software⁷²⁷³⁷⁴. They are still the sellers’ listings, not audited accounts. They suggest the thread’s method has produced modest profits within a year. They also show owners selling within 8 to 12 months, and stores put up for sale are not a fair sample.

A much larger listing. Another Flippa listing describes a research-peptide store launched in October 2025: “Within nine months, the platform reached an annual run-rate of approximately $22 million”. Run-rate means recent monthly sales multiplied by twelve. It states $391,521 of monthly profit, about 21% of sales (our division), and asks $40 million⁵⁴. The figures are the seller’s, and the details are behind a confidentiality agreement.

Court outcomes. Paradigm Peptides, an online store in Indiana, sold peptides, the hormone hCG and SARMs, which are compounds made to act like testosterone²⁸²⁹. The Justice Department’s notice covers purchases between April 2019 and March 2024²⁸. Its case page shows that the owner, Matthew Kawa, pleaded guilty on 10 December 2025 and was sentenced on 30 July 2026 to 5 years and 10 months (70 months) in prison. An employee was sentenced to 1 year and 4 months. Restitution (repayment to victims) was $78,317.52²⁸.

This was more than a labelling case. The Justice Department page says many products sold as SARMs “in fact contained testosterone. Testosterone is a controlled substance.”²⁸ CBS News reports that the owner admitted the store forged lab certificates²⁹. A law firm’s alert gives the charge as introducing unapproved drugs “with intent to defraud or mislead” and says he had ignored FDA warning letters sent in 2020 and 2022²⁶. CBS News calls the sentence “a rare criminal penalty for a seller of peptides that are labeled ‘for research use’”²⁹.

CBS News also reports that prosecutors estimated 54,000 customers in 50 states and 80 countries, and that the owner agreed to forfeit (hand over to the government) $5 million in proceeds²⁹. We did not read those two figures in a court document. This is the only peptide brand we found whose seven figures are tied to a criminal case, and $5 million over about five years is not seven figures a year.

A second prison sentence in 2026, of 21 months, is described in a search summary of a US Attorney’s release from Michigan. It concerns imported peptides sold through websites with a research label. The page would not load for us, so we give no details⁷⁶. In an older case, in 2015, two men in Charlotte pleaded guilty to selling misbranded drugs (drugs labelled in a false or misleading way) through two websites. The Justice Department said they sold about $800,000 over roughly four years while claiming the products were for “Research Purposes” only⁷⁰. Each case concerns only the company and people named in it.

The largest seller closed. Peptide Sciences was, “by most credible estimates, the single largest research peptide vendor in the United States”, in one industry newsletter’s words⁴². On 6 March 2026 its website carried this notice, as quoted by that newsletter: “After careful consideration, Peptide Sciences has made the decision to voluntarily shut down operations and discontinue the sale of our research products.” It gave no reason⁴². Grips puts the store’s 2025 sales at $81.3 million⁴³. The tool still showed sales for the store in August 2026, after it closed, so its figures are rough⁴³.

More closures in 2026. A site that earns commission from vendor links reports that Chameleon Peptides closed on 27 September 2026 after telling customers that Visa had questioned its banks, and that Strate Labs and Eternal Peptides closed in July and September⁴⁴.

Stories from service sellers. An advertising agency’s case study claims an unnamed peptide client made $1.57 million in 30 days on $350,000 of adverts⁴⁷. Another agency claims a client at “$4M+ monthly”, also unnamed⁴⁸. Neither gives proof. Both sell services to peptide brands.

The telehealth version. Search summaries of three sale listings for small GLP-1 telehealth businesses give seller-stated revenue of about $319,000 to $1.8 million and owner earnings (the profit available to a working owner) of $70,000 to $633,000. The smallest was said to be down from nearly $900,000 of revenue at its peak⁶⁷. We could not open the listings. The figures are unaudited, the listing dates are not known, and they may predate the 2025 and 2026 limits on compounding described below.

For context. Of US businesses of any kind born in March 2013, 34.7% were still operating ten years later⁵³. We found no survival figure for peptide stores.

What the rules allow now

The picture below is for the United States, as of 10 October 2026. The regulator and court cases named concern only the companies and people named in them.

The research-store version

The FDA’s consumer page, dated 1 October 2026, says: “FDA has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled ‘for research purposes’ or ‘not for human consumption.’”²²

For the newest products there is no legal consumer route at all: “Retatrutide and cagrilintide cannot be used in compounding under federal law.”²²

On 24 August 2026 the FDA sent warning letters to five online peptide stores, by two law firms’ count²⁶²⁷. We read two of them. The letter to NuScience Peptides says: “Despite statements on your product labeling marketing your products ‘for laboratory, research, and analytical use’ and ‘not intended for human or veterinary use,’ evidence obtained from your website establishes that your products are intended to be drugs for human use.”²³ The letter to TXP Innovations, trading as Tex Peptides, adds that selling sterile water for mixing provides “the means to prepare an injectable drug for human administration”²⁴. Both warn of “seizure and injunction”²³²⁴. A 2025 letter to another store uses the same reasoning²⁵. We found no published reply from these companies. A warning letter is the regulator’s statement, not a court finding.

A law firm sums up the lesson for sellers: “an RUO disclaimer will not overcome dosing, injection, or human-use content” (RUO means research use only)²⁶. So the thread’s advice to keep the site “research focused” and “Have disclaimers” is the approach the FDA has rejected in writing²²³.

Enforcement has been uneven. Public Citizen counted 14 FDA warning letters to retatrutide sellers since 2024: “As of May 2026, 11 of those companies were still advertising retatrutide or other unapproved peptide drugs, and eight continued to sell retatrutide itself.”⁵ So the business depends on enforcement staying thin. The common bad outcomes on this page are warning letters, lost card processing, closure and lawsuits; prison is the rare one^5443029.

Drug makers sue as well. Eli Lilly filed six lawsuits on 12 August 2026 against sellers of retatrutide, four of them research-label stores, asking courts to stop the sales and hand over the profits³⁰. Lilly says it has referred more than 200 people and businesses to the authorities³⁰³¹. These are allegations and the cases are pending. We did not read the complaints, and found no reply from the defendants. A trade publication reports that Novo Nordisk “has filed 130 federal lawsuits” against sellers of GLP-1 copies³².

State boards have acted too. Alabama’s medical board says “under no circumstances is it permissible for a physician to compound, administer, or dispense a non-FDA approved or research grade peptide to a patient”⁶¹. We did not check other countries.

The telehealth version

This route is legal with the right licences, but it is under pressure.

On 3 March 2026 the FDA announced warning letters to 30 telehealth companies over how they marketed compounded GLP-1 drugs³³. Among the faults the FDA named: “advertising drug products branded with the telehealth firm’s name or trademark without qualification, implying they are the compounder”³³. Putting your brand name on the product is the idea of the scheme. Law firms report 25 more letters in June 2026³⁴²⁷.

Supply is narrowing. Pharmacies were allowed to copy semaglutide freely while it was in shortage. That ended in 2025, and on 1 April 2026 the FDA said that adding vitamin B12 can still leave a product “essentially a copy” of the approved drug⁶⁹. Hims & Hers now offers compounded GLP-1 drugs only “on a limited scale”³⁹.

The Federal Trade Commission (FTC) is the US consumer protection agency. In July 2025 the operators of one GLP-1 telehealth firm, NextMed, agreed to settle FTC charges that they used deceptive price and weight-loss claims and fake reviews. Under the consent order they pay $150,000, expected to go to refunds⁵⁹. A settlement is not a court finding, and we found no published reply from the company. FTC guidance for all health products says: “Anyone participating in deceptive marketing is potentially liable under FTC law.”⁶⁰ That reaches affiliates.

What may change

In April 2026 the FDA took 12 peptides off its list of substances that raise safety concerns for compounding, and sent seven, including BPC-157 and TB-500, to an advisory committee³⁵. None is a GLP-1 drug. In July 2026 the panel voted to recommend six of the seven for pharmacy compounding: four on the first day and two of three on the second¹⁸³⁶³⁷. Sources differ on how long a final rule takes: 8 to 12 months in one, 12 to 24 in another³⁷³⁶.

All agree on the main point. A law firm notes that removal “does not, in itself, establish eligibility for compounding”³⁵. LegitScript wrote on 22 September 2026 that these peptides “are not currently eligible for compounding, sale, or use”¹⁸. If the rule is finalised, it opens prescription sales through pharmacies, not web-store sales of vials. This is where the scheme is unproven because it is early; a final FDA rule would settle it.

Who makes money from it

The collected thread points to nothing for sale: we saw no course, link or community in its text². We also found no paid course on building a peptide brand, though we searched in only one wording. The money around a new store goes to these parties:

• Suppliers. Factory prices are $0.60 to $1.23 per milligram on the one table we could read³.
• Payment processors. About 7% of sales at one large store, by its own sale listing⁵⁴.
• Affiliates and influencers. Typically 10% of each sale, and up to 70% of a first order on one listing¹⁹²⁰²¹. One newsletter author with an audience announced he had co-founded a peptide store himself⁴⁹.
• Store builders. One freelancer offers a full brand and store for $8,000 in four weeks. Legal review and a payment account are not in the scope⁵⁸.
• Agencies. They sell advertising accounts and services, and publish the seven-figure stories quoted above⁴⁷⁴⁸.
• LegitScript, on the telehealth route: $3,125 to $4,970 in the first year per website¹⁷.
• Telehealth platforms. One lists doctor visits at $35 or $20 each and identity checks at $0.75 to $1.50⁶⁸.

Every regulator and court action we found was against the sellers of the product. We found none against anyone who taught or supplied them.

The upside

Demand is real. A US public radio report describes a journalist buying a six-month supply of retatrutide direct from a Chinese factory: “I sent $150 in Bitcoin and received a six-month supply in the mail two weeks later.”⁵¹ A secondary source puts US imports of hormone and peptide compounds from China at $328 million in the first nine months of 2025, double the year before⁷¹.

The same facts mean a store’s customers can buy from the store’s own supplier. Paid communities for buyers teach exactly that. One charges $37 a month, showed 310 members and says members learn “how to source directly from manufacturers”; another charges $15 a month⁵⁵⁵⁶. They are competition for a store, not a service to it.

Best documented outcomes, telehealth route

• MEDVi. A GLP-1 telehealth brand started by one founder with about $20,000 and no outside funding, which reported $401 million of revenue and $65 million of profit in 2025, its first full year. These figures come from a business-news site relaying the New York Times⁶³. A trade publication says the Times “was given access to MEDVi’s financials to verify revenue and profits” and that the staff were the founder and his brother, “along with contract engineers, account managers and outside agencies”⁶⁴. We could not open the Times article; the figures are checked by a newspaper, not audited. Platform companies handled “the doctors, pharmacies, shipping and compliance”⁶⁴.

  How it advertised matters. A search of Facebook for “medvi” returned more than 5,000 results, and the founder said “maybe 30%” of its advertising ran through affiliates⁶⁴. Business Insider reported, by the trade publication’s account, that some adverts ran under doctor profiles that appeared not to be real; afterwards the number of active adverts fell to roughly 2,800⁶⁴. The founder’s reported reply: “If we find an affiliate doing this we work to take these ads down.”⁶⁴ On 20 February 2026 the FDA sent MEDVi a warning letter saying its “compounded semaglutide and tirzepatide products are misbranded drugs”, in part because the label showed the MEDVi name⁶⁵. MEDVi’s reported reply is that the website cited belonged to an affiliate agency and that it “never received a letter from the FDA”; the trade publication notes the letter is addressed to MEDVi⁶⁴. A lawsuit filed in March 2026 alleges that MEDVi benefited from affiliate spam; it is pending⁶⁴.

• Hims & Hers. Reported in securities filings (the quarterly figures are unaudited), and very large: $753.2 million of revenue in April to June 2026, of which $262.2 million went on marketing. It made a net loss of $86.3 million in the quarter, against net income of $42.5 million a year earlier, as it cut back compounded GLP-1 drugs³⁹.

• AIOS (formerly Fella Health). An analyst firm, Sacra, estimates $420 million of yearly-rate revenue (one month’s sales multiplied by twelve) in June 2026, with no large outside funding. The same estimates show a fall from $82 million to $54 million in six months of 2025, after the FDA limited compounding and drug makers sued⁶⁶. By Sacra’s account the recovery came from buying a UK pharmacy and selling branded drugs in Britain at cost, at about 20% gross margin, not from its own-brand compounded products⁶⁶. These are estimates, not filings. We did not check the lawsuits.

Best documented outcomes, research-store route. All three are described above. Paradigm Peptides: a $5 million forfeiture as reported by CBS News, ending in prison²⁸²⁹. The large Flippa listing: about $22 million a year after nine months, seller-stated⁵⁴. Peptide Sciences: an estimated $81.3 million in 2025 from a traffic model, closed in March 2026⁴³⁴².

The top tenth or hundredth. We found no data. Nobody publishes how many peptide brands there are or what the typical one earns.

A realistic good result. On the research-store route, the three small Flippa listings are the best evidence: profit of about $3,000 to $16,000 a month within the first year, two of them without paid adverts, by the sellers’ accounts⁷²⁷³⁷⁴. That comes with the legal exposure above, and with a sales tool’s estimate that the tracked market shrank in 2026⁷⁵.

On the telehealth route we have no sourced figure we could open. The three sale listings span $70,000 to $633,000 of owner earnings a year, from search summaries only⁶⁷. For the first year, our estimate is a few hundred thousand dollars of revenue with little or no profit. The basis is the marketing ratios in³⁸ and⁴¹; it is a guess, not a measurement.

New entrants with public backing are funded: Feel Peptides raised $3 million and has a plastic surgeon as medical adviser, and Protocole raised $6 million⁴⁵. Neither reports revenue, and the article does not say which of the three versions each sells.

What it takes to compete

The people with documented success on the legal route have things most readers of the tweet do not.

Proven skill at paid advertising. Every telehealth brand can rent the same doctors and pharmacies, so the product is the same⁶⁴⁶⁸. What differs is the advertising. Hims & Hers spends 35 to 39 cents of each dollar on marketing³⁸³⁹. The largest newcomer’s name appeared on thousands of adverts, partly placed by affiliates, and they drew the questions described above⁶⁴.

Licences and certification before the first advert. LegitScript certification, a telehealth platform with a prescriber in each state, and a payment processor that has approved the business^1317768.

Money to test with. The fixed fees are a few thousand dollars¹⁷. The real cost is advertising spent before it pays back, and legal advice: tens of thousands of dollars by our estimate, with no sourced figure.

Tolerance for sudden rule changes. One estimate shows a third of a company’s revenue gone in six months after a rule change⁶⁶. The FDA has objected to brand names on compounded drugs³³⁶⁵.

Or an existing audience. On the research-store route, the people who enter with an advantage already have followers who buy on their recommendation, or affiliates who do⁴⁹⁷⁴.

On the research-store route the costs to start are low: an $8,000 store build, a first order of stock, an affiliate programme⁵⁸³. What the survivors have is harder to name, because the route depends on not being among the sellers that regulators, card networks or drug makers act against next⁵⁴⁴³⁰. In the rare worst case, with forged certificates and ignored warnings, the result was 70 months in prison²⁸²⁹²⁶.

How to tell early which side you are on

• Can you name the licensed prescriber and the licensed pharmacy behind each sale? If not, you are on the route the FDA calls illegal²².
• Has a mainstream processor approved the business in writing, knowing what it sells?⁷
• Would LegitScript certify the website as it stands?¹⁸
• Have you already run paid adverts that returned more than they cost, for any product? The median health brand gets $1.44 per dollar⁴¹.
• Does your plan still work if the main product is withdrawn by a rule change?⁶⁹

What we did not verify

• The images, videos and replies in the collected thread. We read the posts as text through a third-party reader because x.com blocked us². We did not check anything the account says about itself.
• The $5 million forfeiture and 54,000 customers in the Paradigm Peptides case in a court document. They come from CBS News and a law firm²⁹²⁶. We did not read the charge or the plea agreement.
• A second 2026 prison sentence for selling research-label peptides. The Justice Department page refused us directly and came back empty through a reader⁷⁶. A similar release from Pennsylvania was reported to us and not opened.
• Three of the five FDA letters of 24 August 2026, the FDA’s June 2026 telehealth letters, and the FDA’s own notices on the April and July 2026 peptide decisions. These are from law firms and trade press^262734353637.
• Eli Lilly’s complaints, any defendant’s reply, and the outcome of any drug-maker lawsuit against a small seller³⁰³¹³².
• The New York Times article on MEDVi, the business-news page relaying it (it refused us in the final check), what the founder had done before, and any news of the company after April 2026⁶³⁶⁴.
• The Bloomberg feature on the peptide trade, which blocked us. Its reported figures (one small store at about $100,000 a month; one testing lab near nine figures of revenue) are not used above⁴⁶.
• The telehealth sale listings. The pages blocked us directly and through a reader; figures are from search summaries, and we have the address of only one of the three⁶⁷.
• The accounts behind the Flippa listings, which need an account or a confidentiality agreement^54727374.
• Shopify’s rules for peptide stores, X’s advertising rules for health products, and TikTok Shop’s seller rules⁹.
• Card fees and reserves specific to peptide stores. We have only vendors’ figures¹¹¹²⁵⁴.
• Manufacturers’ price lists, minimum orders, lab-testing prices, shipping cost, refund rates and repeat-purchase rates beyond one seller’s statement. Our per-vial sums use assumptions where marked.
• The cost of winning a telehealth patient and how long patients stay. Studies of how long people stay on GLP-1 drugs exist (a Danish registry study and a US insurer’s report were pointed out to us); we did not open them, so they are not used.
• The current cash prices of branded GLP-1 drugs.
• The non-drug version (collagen, skin-care peptides), beyond one vendor’s guide⁵⁰. The page does not judge it.
• State rules, insurance, customs seizures, and other countries. We read one UK press release on arrests and do not use it⁶².
• The dates of the Meta, Google, Amazon and Stripe policy pages. Most carry no date.
• Skool’s fees, a lab’s report on Peptide Sciences’ products and general business survival figures were read; the first two are not used above⁵⁷⁵².

Sources

1. Does It Pay collection of 1 tweets on this scheme, collected 2026-10-06.
2. The six-post thread behind the collected tweet, read through a third-party reader because x.com refused us. https://api.fxtwitter.com/2/thread/2107363173905150279. Posted 2026-10-06. Read at source on 2026-10-10.
3. Finnrick, retatrutide vendor and price table. https://www.finnrick.com/products/retatrutide. Live page, latest test rows dated 2026-09-25. Read at source on 2026-10-10.
4. Public Citizen, “The Miracle Drug and the Peptide Craze” (report). https://www.citizen.org/article/the-miracle-drug-and-the-peptide-craze-breaking-the-fda/. 2026-06-16. Read at source on 2026-10-10.
5. Public Citizen, news release on retatrutide hospitalisations and enforcement gaps. https://www.citizen.org/news/hospitalizations-enforcement-gaps-influencers-tied-to-unapproved-retatrutide-products/. 2026-06-16. Read at source on 2026-10-10.
6. Stripe, “Prohibited and Restricted Businesses”. https://stripe.com/legal/restricted-businesses. Page date read as 2026-07-14 by two agents and 2026-09-22 by one. Read at source on 2026-10-10.
7. Stripe Support, prohibited and restricted businesses FAQ. https://support.stripe.com/questions/prohibited-and-restricted-businesses-list-faqs. Undated. Read at source on 2026-10-10.
8. Shopify, pricing. https://www.shopify.com/pricing. Undated. Read at source on 2026-10-10.
9. Shopify, Acceptable Use Policy. https://www.shopify.com/legal/aup. Page stamped 2026-10-06. Read at source on 2026-10-10.
10. Corepay, peptide merchant accounts. https://corepay.net/?p=1130. Undated. Read at source on 2026-10-10 (through r.jina.ai).
11. PaymentCloud, “High-Risk Merchant Account Fees”. https://paymentcloudinc.com/blog/high-risk-merchant-account-fees/. First published 2023-01-06, since revised. Read at source on 2026-10-10. Vendor’s general guide.
12. Seamless Chex, “Hidden reserve costs on peptide and SARM merchant accounts”. https://www.seamlesschex.com/deep-dives/hidden-reserve-costs-on-peptide-and-sarm-merchant-accounts-you-should-negotiate. 2026-07-10. Read at source on 2026-10-10. Vendor page.
13. Meta, advertising standards: drugs and pharmaceuticals. https://transparency.meta.com/policies/ad-standards/restricted-goods-services/drugs-pharmaceuticals/. Undated. Read at source on 2026-10-10 (through r.jina.ai).
14. Google Ads policy, healthcare and medicines. https://support.google.com/adspolicy/answer/176031?hl=en. Undated. Read at source on 2026-10-10 (through r.jina.ai).
15. TikTok ads policy, healthcare and pharmaceuticals. https://ads.tiktok.com/help/article/tiktok-ads-policy-healthcare-pharmaceuticals. Undated. Read at source on 2026-10-10.
16. Amazon Seller Central, drugs and drug paraphernalia policy. https://sellercentral.amazon.com/help/hub/reference/external/G200164490. Undated. Read at source on 2026-10-10.
17. LegitScript, healthcare certification pricing. https://www.legitscript.com/certification/healthcare-certification/pricing/. Undated. Read at source on 2026-10-10.
18. LegitScript, “The Peptide Boom: Why So Many Popular Products Are Still Off-Limits”. https://www.legitscript.com/healthcare/the-peptide-boom-why-so-many-popular-products-are-still-off-limits/. 2026-09-22. Read at source on 2026-10-10.
19. iDevAffiliate directory, Biolinx Labs affiliate programme. https://directory.idevaffiliate.com/biolinxlabs/. Undated. Read at source on 2026-10-10.
20. Partnero, Ascend Peptides UK affiliate programme. https://list.partnero.com/programs/515. Undated (2026). Read at source on 2026-10-10.
21. FlexOffers, Prime Science Peptides affiliate programme. https://www.flexoffers.com/affiliate-programs/prime-science-peptides-affiliate-program/. Updated 2026-06-24. Read at source on 2026-10-10. Network listing, not the brand’s own page.
22. FDA, “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss”. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss. 2026-10-01. Read at source on 2026-10-10 (through r.jina.ai).
23. FDA warning letter to NuScience Peptides LLC. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026. 2026-08-24. Read at source on 2026-10-10 (through r.jina.ai).
24. FDA warning letter to TXP Innovations LLC dba Tex Peptides. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/txp-innovations-llc-dba-tex-peptides-735067-08242026. 2026-08-24. Read at source on 2026-10-10 (through r.jina.ai).
25. FDA warning letter to usapeptide.com. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/usapeptidecom-696885-02262025. 2025-02-26. Read at source on 2026-10-10 (through r.jina.ai).
26. McDermott Will & Schulte, “Federal regulators and state boards crack down on RUO peptides”. https://www.mcdermottlaw.com/insights/federal-regulators-and-state-boards-crack-down-on-ruo-peptides/. 2026-09-24. Read at source on 2026-10-10; secondary for the court and FDA facts it reports.
27. ArentFox Schiff, alert on five peptide vendors and research-use-only labels. https://www.afslaw.com/perspectives/alerts/ruo-ined-five-peptide-vendors-learn-research-use-only-not-legal-strategy. 2026-09-18. Secondary.
28. US Department of Justice, US Attorney’s Office, Northern District of Indiana, “United States v. Matthew Kawa” (case page). https://www.justice.gov/usao-ndin/united-states-v-matthew-kawa. Updated 2026-08-03. Read at source on 2026-10-10.
29. CBS News, report on the Paradigm Peptides sentencing. https://www.cbsnews.com/news/peptides-seller-prison-sentence-unapproved-drugs/. 2026-07-30. Read at source on 2026-10-10 (through r.jina.ai); secondary for the court facts.
30. Frier Levitt, “Lilly retatrutide lawsuits: RUO peptide sellers”. https://www.frierlevitt.com/articles/lilly-retatrutide-lawsuits-ruo-peptide-sellers/. 2026-08-18. Secondary.
31. Healio, “Eli Lilly files lawsuits against six companies for allegedly selling retatrutide”. https://www.healio.com/news/endocrinology/20260814/eli-lilly-files-lawsuits-against-six-companies-for-allegedly-selling-retatrutide. 2026-08-14. Secondary.
32. Becker’s Hospital Review, “Lilly, Novo Nordisk’s fight against GLP-1 copycats”. https://www.beckershospitalreview.com/glp-1s/lilly-novo-nordisks-fight-against-glp-1-copycats/. 2026-08-24. Read at source on 2026-10-10 (through r.jina.ai); secondary for the lawsuit counts.
33. FDA, “FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s”. https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s. 2026-03-03. Read at source on 2026-10-10 (through r.jina.ai).
34. Epstein Becker Green, “At the Half: No Free Kicks in FDA’s 2026 Enforcement”. https://www.ebglaw.com/health-law-advisor/at-the-half-no-free-kicks-in-fdas-2026-enforcement. 2026-06-30. Secondary.
35. Goodwin, “FDA Signals Potentially Evolving Stance Toward Compounding of Certain Peptides”. https://www.goodwinlaw.com/en/insights/blogs/2026/05/fda-signals-potentially-evolving-stance-toward-compounding-of-certain-peptides. 2026-05-11. Read at source on 2026-10-10; secondary (law-firm summary of an FDA notice).
36. AJMC, “5 Things to Know About the FDA’s Peptide Reversal”. https://ajmc.com/view/5-things-to-know-about-the-fda-s-peptide-reversal. 2026-08-21. Secondary.
37. Pharmaceutical Executive, report on the FDA advisory committee votes on peptides. https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides. 2026-07-24. Secondary.
38. Hims & Hers Health, Form 10-K for 2025. https://www.sec.gov/Archives/edgar/data/1773751/000177375126000022/hims-20251231.htm. Filed February 2026. Read at source on 2026-10-10.
39. Hims & Hers Health, Form 8-K earnings release for the quarter ended 2026-06-30. https://www.sec.gov/Archives/edgar/data/0001773751/000177375126000161/hims-20260630x8xkearningsr.htm. 2026-08-10. Read at source on 2026-10-10 (through r.jina.ai). Quarterly figures are unaudited.
40. Shopify, e-commerce conversion rate benchmarks. https://www.shopify.com/blog/ecommerce-conversion-rate. Cites Q1 2026 data. Secondary.
41. Triple Whale, Facebook ads benchmarks. https://www.triplewhale.com/blog/facebook-ads-benchmarks. Updated 2026-08-17; data for 2025-08-01 to 2026-07-31. Read at source on 2026-10-10 (through r.jina.ai; the direct route was refused).
42. The Peptide List (Substack), “Peptide Sciences Is Dead”. https://thepeptidelist.substack.com/p/peptide-sciences-is-dead-inside-the. 2026-03-06. Read at source on 2026-10-10; secondary for the store’s notice and sales estimates.
43. Grips Intelligence, peptidesciences.com retailer page. https://gripsintelligence.com/insights/retailers/peptidesciences.com. Data month August 2026. Read at source on 2026-10-10 (through r.jina.ai); the figures are the tool’s estimates.
44. The Peptide Catalog, article on the Chameleon Peptides closure. https://thepeptidecatalog.com/articles/chameleon-peptides-shut-down-alternatives. 2026-10-07. Secondary (affiliate site).
45. Beauty Independent, “Feel Peptides raises $3M”. https://www.beautyindependent.com/feel-peptides-raises-3m-elevating-branding-accessibility-peptides/. 2026-05-28. Read at source on 2026-10-10 (through r.jina.ai).
46. Bloomberg, feature on the peptide rush. https://www.bloomberg.com/features/2026-peptide-legalization-gold-rush/. 2026. Not opened (blocked); secondary, from a search summary only.
47. AdLeaks, peptides case study. https://www.adleaks.com/peptides-case-study/. 2026-05-20. Read at source on 2026-10-10. Agency’s own claim.
48. Peptide Marketing, agency home page. https://peptidemarketing.com/. Undated. Read at source on 2026-10-10. Agency’s own claim.
49. Hunter’s Health Hacks, “Launching a research peptide company”. https://huntershealthhacks.beehiiv.com/p/launching-a-research-peptide-company. 2024-12-14. Read at source on 2026-10-10.
50. Your Next Store, “How to start a peptide store”. https://yournextstore.com/blog/how-to-start-a-peptide-store. 2026-06-09. Read at source on 2026-10-10. Vendor’s estimates.
51. WBUR Here & Now, report on unregulated peptides. https://www.wbur.org/hereandnow/2026/03/24/unregulated-peptides. 2026-03-24. Read at source on 2026-10-10.
52. Finnrick, Peptide Sciences vendor report. https://www.finnrick.com/vendors/peptide-sciences/report. 2026-07-03. Read at source on 2026-10-10.
53. US Bureau of Labor Statistics, business survival, 2013 to 2023. https://www.bls.gov/opub/ted/2024/34-7-percent-of-business-establishments-born-in-2013-were-still-operating-in-2023.htm. 2024. Read at source on 2026-10-10 (through r.jina.ai).
54. Flippa, listing 13019390 (research-peptide store for sale). https://flippa.com/13019390. Undated, live 2026-10-10. Read at source on 2026-10-10 (through r.jina.ai). Seller-stated figures.
55. Skool, Gray Peptides Academy. https://www.skool.com/graypeptidesacademy. Live page. Read at source on 2026-10-10.
56. Skool, Exploring Peptides. https://www.skool.com/exploring-peptides. Live page. Read at source on 2026-10-10.
57. Skool, pricing. https://www.skool.com/pricing. Undated. Read at source on 2026-10-10.
58. Dribbble, “Research Peptide Store Design & Build” service. https://dribbble.com/services/235060-Research-Peptide-Store-Design-Build. Live page. Read at source on 2026-10-10.
59. Federal Trade Commission, press release on NextMed. https://www.ftc.gov/news-events/news/press-releases/2025/07/ftc-takes-action-against-telemedicine-firm-nextmed-over-charges-it-used-misleading-prices-fake. July 2025; final order 2025-12-03. Read at source on 2026-10-10.
60. Federal Trade Commission, Health Products Compliance Guidance. https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance. Date not confirmed. Read at source on 2026-10-10.
61. Alabama Board of Medical Examiners, notice on research-grade peptides. https://www.albme.gov/press-release/board-issues-official-notice-concerning-the-prescribing-of-non-fda-approved-research-grade-peptides. May or June 2026; secondary sources differ and the page shows no date. Read at source on 2026-10-10.
62. UK Medicines and Healthcare products Regulatory Agency, “Two arrested during the MHRA’s largest ever seizure of unlicensed weight loss medicines”. https://www.gov.uk/government/news/two-arrested-during-the-mhras-largest-ever-seizure-of-unlicensed-weight-loss-medicines. 2026-05-29. Read at source on 2026-10-10.
63. Dealroom, report on MEDVi (relaying the New York Times of 2026-04-02). https://dealroom.co/news/127216-from-20k-to-1-8b-in-revenue-how-one-founder-built-a-telehealth-giant-wit/. 2026-04-05. Secondary; opened earlier on 2026-10-10, refused us in the final check.
64. Drug Discovery & Trends, article on MEDVi, the New York Times and the FDA. https://www.drugdiscoverytrends.com/the-new-york-times-spotlighted-medvi-the-fda-had-already-warned-the-self-proclaimed-fastest-growing-company-in-history/. 2026-04-04, later updated. Read at source on 2026-10-10; secondary for the New York Times, Business Insider and court facts it reports.
65. FDA warning letter to MEDVi, LLC. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medvi-llc-dba-medvi-721455-02202026. 2026-02-20, posted 2026-04-14. Read at source on 2026-10-10 (through r.jina.ai).
66. Sacra, research note on AIOS. https://sacra.com/research/400m-year-glp1-wrapper/. 2026-07-20. Read at source on 2026-10-10; secondary (analyst estimates).
67. BizQuest, “Nationwide Cash-Pay GLP-1 Telehealth Platform” and similar listings on BizQuest, BizBuySell and LoopNet. https://www.bizquest.com/business-for-sale/nationwide-cash-pay-glp-1-telehealth-platform/BW2538024/. Listing dates not visible. Secondary (search summaries; the pages blocked us directly and through r.jina.ai; only this one listing address is known).
68. Bask Health, plans. https://bask.health/plans. Undated. Read at source on 2026-10-10 (through r.jina.ai).
69. FDA, “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize”. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize. Entry dated 2026-04-01, page updated 2026-09-16. Read at source on 2026-10-10 (through r.jina.ai).
70. US Department of Justice, US Attorney’s Office, Western District of North Carolina, “Two Charlotte Men Plead Guilty To Selling Misbranded Drugs”. https://www.justice.gov/usao-wdnc/pr/two-charlotte-men-plead-guilty-selling-misbranded-drugs. 2015-03-19. Read at source on 2026-10-10.
71. Ethos, “The peptide gray market has a serious ER problem” (citing US customs data). https://the-ethos.co/the-peptide-gray-market-has-a-serious-er-problem/. 2026-05-15. Secondary.
72. Flippa, listing 12893835 (research-peptide store, United States). https://flippa.com/12893835. Undated, live 2026-10-10. Read at source on 2026-10-10. Seller-stated figures, marked by Flippa as vetted and data verified.
73. Flippa, listing 13272695 (peptidelabsinc.com). https://flippa.com/13272695. Undated, live 2026-10-10. Read at source on 2026-10-10. Seller-stated figures, marked by Flippa as a verified listing.
74. Flippa, listing 13063489 (research-peptide store selling to Australia). https://flippa.com/13063489. Undated, live 2026-10-10. Read at source on 2026-10-10. Seller-stated figures, marked by Flippa as vetted and data verified.
75. Grips Intelligence, “Peptide and SARM Suppliers” industry page. https://gripsintelligence.com/insights/industries/health-beauty/peptide-and-sarm-suppliers. Data month August 2026. Read at source on 2026-10-10; the figures are the tool’s estimates.
76. US Department of Justice, US Attorney’s Office, Western District of Michigan, press release on a sentencing of 2026-07-23. https://www.justice.gov/usao-wdmi/pr/2026_0723_Piper_Sentencing_PR. 2026-07-23. Not opened (refused directly, empty through r.jina.ai); secondary, from a search summary only.

Corrections

If you are quoted or named on this page and think something is wrong, want your reply shown beside it, or want to be removed, write to [email protected]. We aim to reply within 14 days, and always within one month. Factual errors are corrected with a dated note here. A sentence that is seriously disputed comes down while we check it.

Change log: (empty)